JOP20230132A1 - أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل - Google Patents

أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل

Info

Publication number
JOP20230132A1
JOP20230132A1 JOJO/P/2023/0132A JOP20230132A JOP20230132A1 JO P20230132 A1 JOP20230132 A1 JO P20230132A1 JO P20230132 A JOP20230132 A JO P20230132A JO P20230132 A1 JOP20230132 A1 JO P20230132A1
Authority
JO
Jordan
Prior art keywords
disease
diseases
heart disease
pyrazolopiperidine
heart
Prior art date
Application number
JOJO/P/2023/0132A
Other languages
Arabic (ar)
English (en)
Inventor
Collin-Kroepelin Marie-Pierre
Alexandros Vakalopoulos
Mathar Ilka
Mondritzki Thomas
Hudson Hofmeister Lucas
Dieskau Andre
Sandner Peter
Stellfeld Timo
Alan Webster Robert
Wunder Frank
Schmeck Carsten
DIETZ Lisa
Candish Lisa
BOULTADAKIS-ARAPINIS Melissa
Ortega Hernandez Nuria
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of JOP20230132A1 publication Critical patent/JOP20230132A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2023/0132A 2020-12-10 2023-06-08 أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل JOP20230132A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
JOP20230132A1 true JOP20230132A1 (ar) 2023-06-08

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0132A JOP20230132A1 (ar) 2020-12-10 2023-06-08 أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل

Country Status (30)

Country Link
US (1) US20240051935A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552583A (cg-RX-API-DMAC7.html)
KR (1) KR20230118144A (cg-RX-API-DMAC7.html)
CN (1) CN116710439B (cg-RX-API-DMAC7.html)
AR (1) AR124297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021393988A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204495A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001632A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007335A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230242A (cg-RX-API-DMAC7.html)
DK (1) DK4259617T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000115A (cg-RX-API-DMAC7.html)
EC (1) ECSP23040828A (cg-RX-API-DMAC7.html)
ES (1) ES2997117T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259617T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247649B (cg-RX-API-DMAC7.html)
HR (1) HRP20241543T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069255T2 (cg-RX-API-DMAC7.html)
IL (1) IL303296A (cg-RX-API-DMAC7.html)
JO (1) JOP20230132A1 (cg-RX-API-DMAC7.html)
LT (1) LT4259617T (cg-RX-API-DMAC7.html)
MX (1) MX2023006903A (cg-RX-API-DMAC7.html)
PE (1) PE20231501A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259617T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259617T (cg-RX-API-DMAC7.html)
RS (1) RS66294B1 (cg-RX-API-DMAC7.html)
SA (1) SA523441083B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259617T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022122914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法
AU2024348074A1 (en) * 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
TW202535380A (zh) * 2024-01-30 2025-09-16 大陸商海思科醫藥集團股份有限公司 吡唑羧酸衍生物及其在醫藥上的應用
WO2026145681A1 (zh) * 2025-01-03 2026-07-09 上海齐鲁制药研究中心有限公司 杂环羧酸类衍生物、其制备方法及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101939053A (zh) * 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
MX338887B (es) * 2012-09-07 2016-05-04 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
US20170313665A1 (en) 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CA3204595A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
WO2022122917A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
US20240051935A1 (en) 2024-02-15
IL303296A (en) 2023-07-01
AU2021393988A9 (en) 2024-09-19
SA523441083B1 (ar) 2025-06-12
CN116710439A (zh) 2023-09-05
CO2023007335A2 (es) 2023-06-09
ECSP23040828A (es) 2023-07-31
AR124297A1 (es) 2023-03-15
FI4259617T3 (fi) 2024-11-27
JP2023552583A (ja) 2023-12-18
DOP2023000115A (es) 2023-07-16
LT4259617T (lt) 2024-12-10
EP4259617A1 (en) 2023-10-18
CA3204495A1 (en) 2022-06-16
GEAP202316287A (en) 2023-09-11
CL2023001632A1 (es) 2023-11-10
HRP20241543T1 (hr) 2025-01-03
ES2997117T3 (en) 2025-02-14
GEP20247649B (en) 2024-07-25
MX2023006903A (es) 2023-06-26
CN116710439B (zh) 2026-05-26
RS66294B1 (sr) 2025-01-31
KR20230118144A (ko) 2023-08-10
EP4259617B1 (en) 2024-10-23
TW202237589A (zh) 2022-10-01
PT4259617T (pt) 2024-12-05
WO2022122914A1 (en) 2022-06-16
SI4259617T1 (sl) 2025-02-28
PE20231501A1 (es) 2023-09-26
PL4259617T3 (pl) 2025-03-17
HUE069255T2 (hu) 2025-02-28
DK4259617T3 (da) 2024-12-09
CR20230242A (es) 2023-07-19
AU2021393988A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JOP20230130A1 (ar) أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل
CR20230242A (es) Ácidos pirazol piperidin carboxílicos sustituidos
Hansell et al. Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension
Sciarretta et al. Role of the renin–angiotensin–aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction
Prasad Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality
Coppolino et al. Acute kidney injury in patients undergoing cardiac surgery
Schulman et al. Activated prothrombin complex concentrate for dabigatran-associated bleeding.
Ascione et al. Myocardial injury in hypertrophic hearts of patients undergoing aortic valve surgery using cold or warm blood cardioplegia
Moreno-Blas et al. Connecting chaperone-mediated autophagy dysfunction to cellular senescence
Raimundo et al. Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life‐threatening triad
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
Tian et al. Risk factors for new-onset cardiac valve calcification in patients on maintenance peritoneal dialysis
Mun et al. Role of hydrogen sulfide in cerebrovascular alteration during aging: J. Mun et al.
EA201070084A1 (ru) Новое применение известных фармакологически активных химических соединений
Cartotto et al. Vasopressin for the septic burn patient
Kahn Atherosclerosis and Aging—Insights into the Role of the Endothelial Glycocalyx in Cardiovascular Health
Berbari et al. Chronic kidney disease and renovascular interactions
EL-Adawy et al. Fibroblast growth factor-23: A possible cause of pulmonary hypertension and left ventricle hypertrophy in hemodialysis patients
MX2018005359A (es) Pirroloisoindolonas nuevos inhibidores de la enzima convertidora de angiotensina (iecas) para el tratamiento de la hipertension arterial.
Sato et al. Prevalence of Seasonal Variation in Patients with Heart Failure with Preserved Ejection Fraction
Raikou et al. METABOLIC ACIDOSIS AND ox-LDL AS RISK FACTORS FOR CARDIOVASCULAR DISEASE IN PATIENTS ON RENAL REPLACEMENT THERAPY
Potgieter Etiology of myofascial pain and dysfunction syndrome leading to active trigger-points with Traumeel's treatment intersection.
SC Naide, M.: Treatment of Leg Ulcers With Blood and Concentrated Plasma. Am.
Veerakul et al. Fatal and Near Fatal Acute Ascending Aortic Dissection: Two Case Reports with Different Cardiac Manifestations
WANG et al. Study of the relation between serum adiponectin and coronary artery calcification score in patients with chronic kidney disease